Wednesday, September 29, 2021 David Cescon MD, PhD, is a Medical Oncologist and Clinician Scientist at the Princess Margaret Cancer Centre, where his clinical practice is devoted to the care of patients with breast cancer. His research integrates laboratory and clinical studies, focused on the identification of breast cancer therapeutic vulnerabilities and determinants of drug response and resistance. Leveraging genomic tools, including liquid biopsy, the overarching goal of this work is to advance the delivery of precision therapy to improve breast cancer outcomes through both prevention and treatment of metastatic disease. Dr. Cescon has worked closely with the IND group over the last several years, including on the Stand Up to Cancer Canada Dream Team Trials of CFI-400945, CFI-402257 and CX-5461. He is a previous recipient of the CCTG Elizabeth Eisenhauer IND Young Investigator Award, as well as the Young Investigator and Advanced Clinical Development Awards from ASCO. "Having had the opportunity to work closely with the IND group over the last several years on the Stand up to Cancer Canada Breast Cancer Trials and on the launch of our Breast Cancer Liquid Biopsy Platform Study, I’m looking forward to contributing to the continuing success of this important CCTG Program that seeks to bring novel therapies and strategies to patients across Canadal," says Dr. Cescon. CCTG and the IND program would like to extend our gratitude to the past committee chair Dr. Rosalyn Juergens and current chair Dr. Quincy Chu, for their important contributions to the IND portfolio for the group.
